Acute myeloid leukemia with mixed phenotype is characterized by stemness transcriptomic signatures and limited lineage plasticity

Running title: Acute myeloid leukemia with mixed phenotype

Pallavi Galera[1,*], Deepika Dilip[2,*], Andriy Derkach[3], Alexander Chan[1], Yanming Zhang[4], Sonali Persuad[5], Tanmay Mishera[5], Ying Liu[1,6], Christopher Famulare[7], Qi Gao[1], Douglas A. Mata[6], Maria Arcila[1,6], Mark B. Geyer[8,9], Eytan Stein[8], Ahmet Dogan[1], Ross L. Levine[2,5,7,8], Mikhail Roshal[1], Jacob Glass[2,7,8], Wenbin Xiao[1,7]

[1]Hematopathology Service, Department of Pathology and Laboratory Medicine

[2]Center for Epigenetics Research

[3]Department of Epidemiology & Biostatistics

[4]Cytogenetics Laboratory, Department of Pathology and Laboratory Medicine

[5]Molecular Cancer Medicine Service, Human Oncogenesis & Pathogenesis Program

[6]Diagnostic Molecular Laboratory, Department of Pathology and Laboratory Medicine

[7]Center for Hematologic Malignancies

[8]Leukemia Service, Department of Medicine

[9]Cell Therapy Service, Department of Medicine

Memorial Sloan Kettering Cancer Center, New York, NY, USA

Correspondence: Wenbin Xiao (xiaow@mskcc.org) and Jacob Glass (glassj@mskcc.org)

* These authors equally contribute to this study.

Part of this work was presented at USCAP 109th Annual Meeting 2020, Society for Hematopathology/ European Association for Hematopathology workshop 2020, American Society of Hematopathology Annual meeting 2021 and the first Workshop on Lineage infidelity/plasticity and cell of origin of hematologic malignancies 2022.

Words: 3981
Figures: 6
Tables: 1
Supplemental Figures: 6
Supplemental Tables: 4
References: 68

Key points:

- AML-MP clinically and biologically resembles AML but differs from MPAL.
- AML-MP shows *RUNX1* mutations, stemness signatures and limited lymphoid lineage plasticity.

ABSTRACT (250 words)

Mixed phenotype (MP) in acute leukemias poses unique classification and management dilemmas and can be seen in entities other than de novo mixed phenotype acute leukemia (MPAL). Although WHO classification empirically recommends excluding AML with myelodysplasia related changes (AML-MRC) and therapy related AML (t-AML) with mixed phenotype (AML-MP) from MPAL, there is lack of studies investigating the clinical, genetic, and biologic features of AML-MP. We report the first cohort of AML-MRC and t-AML with MP integrating their clinical, immunophenotypic, genomic and transcriptomic features with comparison to MPAL and AML-MRC/t-AML without MP. Both AML cohorts with and without MP shared similar clinical features including adverse outcomes but were different from MPAL. The genomic landscape of AML-MP overlaps with AML without MP but differs from MPAL. AML-MP harbors more frequent *RUNX1* mutations than AML without MP and MPAL. *RUNX1* mutations did not impact the survival of patients with MPAL. Unsupervised hierarchal clustering based on immunophenotype identified biologically distinct clusters with phenotype/genotype correlation and outcome differences. Furthermore, transcriptomic analysis showed an enrichment for stemness signature in AML-MP and AML without MP as compared to MPAL. Lastly, MPAL but not AML-MP often switched to lymphoid only immunophenotype after treatment. Expression of transcription factors critical for lymphoid differentiation were upregulated only in MPAL, but not in AML-MP. Our study for the first time demonstrates that AML-MP clinically and biologically resembles its AML counterpart without MP and differs from MPAL, supporting the recommendation to exclude these patients from the diagnosis of MPAL. Future studies are needed to elucidate the molecular mechanism of mixed phenotype in AML.

Key words: Mixed phenotype, acute myeloid leukemia, therapy-related, myelodysplasia related, RUNX1, genomics, transcriptome, immunophenotype, lineage switch, lineage plasticity

INTRODUCTION

Mixed phenotype, defined by the presence of two or more lineage distinct blast populations or a single blast population with lineage ambiguity/promiscuity, is characteristic for de novo mixed phenotype acute leukemia (MPAL) but can also be rarely seen in other types of acute leukemia. Specifically, AML with myelodysplasia-related changes (AML-MRC) and therapy-related AML (t-AML) can manifest as mixed phenotype (referred to as AML-MP), which poses unique classification and management dilemmas. Although the WHO classification of hematolymphoid tumors (2017) empirically recommends excluding AML-MP from the diagnosis of MPAL, [1,2] there is a complete lack of studies investigating the clinical, genetic and biologic features of AML-MP except a few single case reports. [3,4] Studies have shown that regimens directed towards acute lymphoblastic leukemia (ALL) result in better outcome in patients with MPAL;[5-10] whereas, liposomal formula of cytarabine and daunorubicin has become the standard of care for patients with AML-MRC and t-AML.[11] Therefore, a better delineation between AML-MP and MPAL is urgently needed for clinical decision making.

Genetically, MPAL often harbor fusions involving *BCR::ABL1*, *KMT2A*, *ZNF384*, *BCL11B* and *PICAML::MLLT10*,[12] and mutations in *PHF6*, *DNMT3A*, *NOTCH1* and *WT1*. [13-17] In contrast, AML-MRC is enriched for MDS-defining cytogenetic abnormalities and so-called "MR" gene mutations (i.e., *SRSF2*, *SF3B1*, *U2AF1*, *ZRSR2*, *ASXL1*, *EZH2*, *BCOR*, and *STAG2* with or without *RUNX1*).[18,19] *TP53* mutations and monosomal/complex karyotypes are frequent in t-AML.[20] The genetic landscape of AML-MP is completely unknown. Furthermore, the newly proposed WHO2022 and ICC2022 classifications[12,21] of hematolymphoid tumors both include MR gene mutations as one of the diagnostic criteria for AML-MR. ICC2022 (but not WHO2022) further includes *RUNX1* mutations to the list of MR genes while removes t-AML as an entity. These drastic changes create uncertainties in the diagnostic algorithm of MPAL. Although WHO2022/ICC2022 both recommend classifying acute leukemia with mixed phenotype and *MR/RUNX1* mutations as AML-MR, there is completely lack of data to verify it. Relatedly, it is uncertain whether therapy-related history still matters or not[22].

In this study, we report the largest cohort of AML-MP to this date integrating the clinical, immunophenotypic, genetic, and transcriptomic features, with comparison to MPAL and AML without MP. We demonstrate that 1) The clinical, genetic, and transcriptomic signatures of AML-MP closely resemble that of AML without MP and differs from that of MPAL; 2) AML-MP has frequent *RUNX1* mutations and is enriched for stemness signatures; 3) *RUNX1* mutations (with or without MR) and complex karyotype do not impact the outcome of MPAL; 4) AML-MP, despite mixed phenotype, has limited lymphoid lineage plasticity compared to MPAL.

METHODS

Patient cohorts

The MSKCC pathology database was searched from January 2014 to December 2022 for a new diagnosis of "acute leukemia" or "acute myeloid leukemia" and/or "mixed phenotype". A second search was performed on flow cytometry reports with "abnormal myeloid blast" and/or "abnormal immature T cells" and/or "abnormal immature B cells". The definition of mixed phenotype was based on the WHO Classification of haematolymphoid tumours 2017.[2] In this study, flow cytometric evaluation was used, and the lineage assignment was independently confirmed by at least 2 of the participating board-certified hematopathologists (P.G., A.C., M.R. and W.X.). Another cohort of 100 patients newly diagnosed as AML-MRC or t-AML without MP was also included for comparison. The clinical, morphologic, immunophenotypic, cytogenetic and molecular results of all patients at initial diagnosis were manually re-annotated. This study was approved by the institutional review board (IRB) at MSKCC, and informed consents were obtained from all patients.

Detailed methods including chromosome and FISH analysis, flow cytometry (Table S1) and cell sorting, RNA sequencing and statistical analysis are included in supplemental data. For original data, please contact xiaow@mskcc.org.

RESULTS

Clinical characteristics of AML-MP

A total of 137 newly diagnosed patients with ≥20% blasts and mixed phenotype were initially identified. Patients with a diagnosis of blast phase of chronic myeloid leukemia (CML) (18, 13%), blast phase of *BCR::ABL1* negative myeloproliferative neoplasms (MPN) (3, 2.2%), B-lymphoblastic leukemia/lymphoma (B-ALL) with isolated myeloperoxidase expression (7, 5.1%), AML with recurrent genetic abnormalities (7, 5.1%), and myeloid/lymphoid neoplasms with eosinophilia and rearrangements (2, 1.5%) were excluded. The remaining 55 (40%) patients of AML (40 AML-MRC and 15 t-AML) with mixed phenotype (AML-MP) and 45 (33%) patients of MPAL were included in this study (**Figure 1A and Table S2**). Therefore, only a third of acute leukemia with mixed phenotype is *bona fide* MPAL. Of note, 26 out of 40 (65%) AML-MRC with MP had no history of MDS or MDS/MPN and the diagnosis was based on the presence of MDS cytogenetic abnormalities (MDS-CG) (**Figure 1B**). One patient with neither history nor MDS-CG had a mutational profile (*ASXL1*, *RUNX1*, *SRSF2*, three *TET2*, two *STAG2*, *CEBPA*, *FLT3*, and *MED12*) typical for AML and therefore was eventually classified as AML-MP after group consensus. The overall frequency of mixed phenotype in AML-MRC and t-AML was 3.3% (55/1679) with 2.8% (40/1429) in AML-MRC and 6% (15/250) in t-AML, respectively.

We compared the clinical features of AML-MP to that of AML without MP (63 AML-MRC and 37 t-AML) and MPAL (**Table 1**). The median age at diagnosis of AML-MP was 66.5 years, significantly higher than that of MPAL (42 years, p<0.0001) but similar to that of AML without MP (70 years). All 3 cohorts had male preponderance. Both AML cohorts (with or without MP) had fewer peripheral/bone marrow blasts but more severe leukopenia and thrombocytopenia than MPAL. The AML-MP cohort included 30 (54.5%) B/Myeloid (B/M), 20 (36.4%) T/M and 5 (9.1%) B/T/M phenotype, similar to MPAL [26 (57.8%), 16 (35.6%), and 2 (4.4%), respectively]. One patient with MPAL had a rare T/B phenotype. Fourteen (25.5%) cases of AML-MP revealed extramedullary involvement (7 involving skin and 7 lymph node), higher than that seen in AML without MP cases (8%, 5 skin and 3 lymph node involvement, p=0.007). While the MPAL cohort demonstrated similarly high numbers of cases with extramedullary involvement (12/45, 26.7%) the distribution was quite different from AML-MP with almost all MPAL cases revealing nodal and only 1 patient showing skin involvement (p=0.03, **Table S3**).

Genomic landscape of AML-MP

Mutational profiles were revealed by targeted NGS sequencing studies in 52 of 55 AML-MP, 37 of 45 MPAL and 99 of 100 AML without mixed phenotype (**Figure 2**). Mutations in *TET2*, *FLT3*, *KRAS*, *PTPN11*, *IDH1*, *IDH2*, and *CEBPA* showed no statistical difference among the 3 cohorts. Notably, mutations in *TP53* were absent from MPAL. Although MR gene coverage was limited in most patients, *SRSF2*, *U2AF1*, *BCOR*, *EZH2*, *STAG2* and *SETBP1*, while variably common in both AML cohorts, were notably absent from MPAL. Mutations in other MR genes such as *ASXL1* and *SF3B1* were also rare in MPAL. Conversely, MPAL was enriched for mutations in *PHF6* and fusions in *MLL*, *BCR::ABL1* and *PICALM::MLLT10*. *RUNX1* mutations, although common in all 3 cohorts, were significantly more frequent in AML-MP [21/52 (40.4%) vs 23/99 (23%) in AML without MP, p=0.02 and 7/35 (20%) in MPAL, p=0.06]. *NRAS* mutations were also more frequently present in AML-MP (15.7% vs 4% AML without MP, p=0.02). In contrast, mutations in *SRSF2*, *U2AF1* and *SETBP1* were more common in AML without MP than AML-MP (**Figure 2B**).

MDS defining cytogenetic abnormalities were frequent in AML-MP (80%) and AML without MP (66%) (**Table 1**). In contrast, only 9/45 (20%) patient with MPAL had complex karyotypes (CK, **Table S4)**: 1 had a T/B (no myeloid) phenotype, 1 had a *PICALM-MLLT10* translocation with isochromosome 17q(10), 5 had other balanced translocations and CK not involving chr. 5, 7 or 17, and finally 2 had a hyper-diploid clone (1 with a sub-clonal del5q). Thus, despite of atypical complex karyotypes, these 9 patients were classified as MPAL.

Unsupervised hierarchal clustering based on immunophenotyping

To explore the immunophenotype in an unbiased manner, raw clinical flow cytometry data in the form of FCS files were computationally analyzed in an unsupervised fashion (see Supplemental data). The viable, dim CD45 expressing cells were automatedly extracted to loosely capture leukemic blasts. 36 distinct populations derived from M1 and M2 tubes were identified in all the samples from 3 cohorts using a self-organizing map (SOM) (**Figure S1-S3**). Hierarchical clustering using these populations revealed 8 distinct clusters of patients (**Figure 3**). Most clusters exhibited a relatively uniform lineage and composition of either AML without MP, AML-MP or MPAL, but some were more variable suggestive of either suboptimal separation related to limited protein markers available or a potential biological similarity among subsets of these cohorts.

To better understand the biology driving the clustering, disease type, cytogenetic changes, molecular alterations and manually annotated immunophenotype were evaluated for enrichment within each cluster. A B/Myeloid mixed phenotype were primarily observed in Clusters 1 (10/20, 50%), 3 (7/16, 43.8%), and 8 (8/8, 100%). Cluster 3 consisted of AML-MP cases with B/Myeloid mixed phenotype and an enrichment in *RUNX1* mutations (11/16, 69%) with high levels of CD34 and CD13 expression. Clusters 8 represented MPAL with B/Myeloid phenotype with significantly lower levels of CD117 expression (p=0.005). Cluster 8 had more frequent *BCR::ABL1* fusions (5/8, 62.5%), and cluster 1 had various other fusions**.** Cluster 6 was composed almost entirely of patients with AML with or without MP, mostly harboring TP53 mutations and a monosomal and/or complex karyotype (11/16, 68.8%). Cluster 6 also had high levels of CD34 and CD117 expression but very low levels of CD38 expression, an immunophenotype enriched for hematopoietic/leukemic stem cells [23,24]. Despite the lack of T-cell markers in our FCS files, this approach identified cluster 5 with a T/M phenotype (6/6, 100%) and enrichment for mutations in *DNMT3A*, *NRAS* and *IDH2*,[14] composed of predominantly AML-MP with T/M phenotype and a few MPAL with T/M phenotype, suggesting some higher dimensional immunophenotypic features may be only appreciated by our computational analysis. Cluster 4 consisted predominantly of patients with a prior history of MDS/MPN (13/18, 72.2%) and mostly without MP (17/18, 94.4%). The majority of cases in Cluster 2 were AML without MP (13/22, 59%). Altogether, these data demonstrate that immunophenotype based hierarchical clustering may reveal disease biology linking phenotype and genotype.

AML-MP has similar outcomes to AML without MP but inferior to MPAL

The overall survival (OS) was inferior in patients with AML-MP cohort in comparison to MPAL (median: 10.3 vs 42.8 months, p<0.0001; **Figure 4A**) but similar to the AML without MP (median: 7.1 months, p=0.3; **Figure 4A**). AML-MP patients were also less likely to achieve complete remission after induction in comparison to MPAL (p<0.001, Table 1). In a multivariable analysis, after adjusting for the set of major confounders such as age, treatment with intension to cure, cytogenetic risk stratification category[25] and allotransplant, MPAL was still significantly associated with better OS (**Figure 4B**). We also studied the association between unsupervised hierarchical clustering and the outcome. Both clusters 1 and 8 were enriched for MPAL with B/M phenotype, however, cluster 8 had higher ratio of *BCR::ABL1* translocations and showed superior OS (**Figure 4C**). Conversely, cluster 6, characterized by *TP53* mutations had inferior OS. Surprisingly, cluster 5, enriched for T/M phenotype and composed of a

mixture of AML-MP and MPAL also had adverse OS. Other clusters showed intermediate OS. Association between 8 clusters and OS remained significant after adjusting for the same set of confounders (p=0.007).

MR/RUNX1 gene mutations or complex karyotypes do not confer inferior outcome to MPAL

As both WHO2022 and ICC2022 classifications[12,21] expand the AML-MR category by including patients harboring *MR/RUNX1* gene mutations regardless of history and/or cytogenetics, we investigated if the newly included *MR/RUNX1* gene mutations in otherwise MPAL would confer an inferior outcome and thus would suggest reclassifying it as AML-MP. Eight patients of MPAL harbored *MR/RUNX1* gene mutations: 1 *RUNX1/ASXL1*, 1 *RUNX1/SF3B1*, 1 *ASXL1* and 5 *RUNX1*. Interestingly, these 8 patients had similar OS to the remaining MPAL patients but superior to AML-MP (median survival: 65 vs 10 months, p=0.014; **Figure 4D**). The subgroup of patients (n=3) with WHO2022 *MR* gene mutations was too small for outcome analysis.

To examine if complex karyotypes are associated with inferior outcome in MPAL, overall survival was compared between MPAL patients with or without complex karyotype (**Figure 4E**), which showed no difference. Therefore, complex karyotype may not confer inferior outcome in *bona fide* MPAL patient after excluding AML-MP.

AML-MP shares upregulated stemness gene sets with AML without MP

Gene-expression analysis was performed on flow sorted myeloid- vs T-lineage leukemic blasts using RNA-seq to compare the genetic programs differentiating MPAL from AML-MP cases. Principal component analysis revealed two distinct lineage-based groups: one primarily consisting of MPAL samples and the other with both AML without MP and AML-MP (**Figure 5A**). This was further confirmed when unsupervised clustering was performed on RNA-seq data, resulting in two groups akin to the PCA (**Figure S4**). Flow marker annotations indicated higher CD38 and lower CD34 levels in the MPAL cluster compared to the AML-MP/AML group, suggesting a more differentiated immunophenotype of MPAL (**Figure S4**).

To determine the specific lineage features separating MPAL from AML-MP, pathway analysis was performed using custom hematopoietic lineage gene sets derived from a published set of flow sorted hematopoietic stages derived from normal bone marrow samples[26]. Genes which were characteristic of each stage were identified using the Kruskal Wallis test statistic. Enrichment analysis using these sets revealed a significant HSC gene set enrichment in the AML-MP samples compared to MPAL in both myeloid ($p< 0.001$) and T blasts ($p< 0.001$) (**Figure 5B**). In addition, monocytic and CD4 T-cell lineages were enriched in myeloid blasts ($p<0.001$) and T-blasts ($p<0.001$) sorted from MPAL, respectively.

GSEA using published gene sets in MSigDB[27,28] revealed significant enrichment in gene sets characterized by leukemic stem cells (**Figure 5C**). GSVA scores were calculated for these gene sets and compared: the results highlighted a separation between MPAL and AML samples both with and without MP (**Figure 5D**). Among stem cell expression gene-sets, AML-MP samples had higher GSVA scores compared to MPAL cases. When comparing GSVA scores, AML-MP samples aggregated with AML without MP samples rather than MPAL. Sample-specific pathway enrichments using selected AML and hematopoietic stem cell gene sets revealed a greater enrichment of hematopoietic stem cells,[29] Valk cluster 15[30], upregulation of targets of NUP89/HOXA9 fusion in CD34+ hematopoietic cells,[31] and upregulated genes in leukemic stem cells[32] in AML and AML-MP samples. Unsupervised analysis of these enrichment scores identified two main sample groups: one composed entirely of AML and AML-MP samples, and the other composed almost entirely of MPAL samples (**Figure 5D**). To identify the genes driving this separation, the genes composing these pathways were examined individually (**Figure S5**). Among the genes identified were several master regulators of hematopoiesis such as *MEIS1*,

HOXB2, and *HOXB3* (**Figure 5E**). Notably, one patient of AML-MP clustered with MPAL, displaying that at transcriptomic level it was closer to MPAL than AML-MP (**Figure 5D-E**). Therefore, this patient was biologically closer to MPAL despite technically meeting criteria of t-AML.

AML-MP has limited lymphoid lineage plasticity with lower expression levels of lymphoid transcription factors

At diagnosis, the proportion of myeloid blasts in AML-MP was higher than that in MPAL (61%±35% vs 39%±37%, p=0.009, Wilcox test), while the portion of lymphoid blasts was comparable (Figure 6A). A subset of patients exhibited lineage shift from diagnosis either post-treatment or at a relapse event (**Figure 6A-C**). 7 AML-MP and 13 MPAL patients with persistent disease exhibited lineage shifts after induction therapy. Of the 24 patients who obtained complete remission but later relapsed, 8 (5 AML-MP, 3 MPAL) switched immunophenotypes between diagnosis and relapse and 6 of them became myeloid only. Interestingly, 3 patients had second relapse and the immunophenotype returned from myeloid only back to the original mixed phenotype. Altogether, among the patients remaining positive for disease after treatment (either post induction or relapse), comparable portion of MPAL and AML-MP patients displayed a myeloid-only immunophenotype (4/28, 14.2% vs 9/40, 22.5%, p=0.5, **Figure 6D**). Strikingly, MPAL patients frequently shifted to lymphoid (either B- or T-lineage)-only blasts (10/28, 35.7%), while patients with AML-MP rarely did (1/40, 2.5%, p=0.0003), suggesting a biological difference in *bona fide* lymphoid differentiation potential between AML-MP and MPAL.

To provide mechanistic insights into diminished lymphoid differentiation potential in AML-MP, we evaluated mRNA expression levels of a list of transcription factors that are critical for myeloid versus lymphoid lineage commitment (**Figure S6**). Consistent with an enrichment for stemness signatures as shown by pathway analysis (see Figure 5), expression of *MEIS1*, *TAL1* and *GATA2*, all critical for HSC functions [33-36], was significantly higher in AML and AML-MP than in MPAL (**Figure 6E**). *SPI1* expression (encoding PU.1), a transcription factor indispensable for both myeloid and lymphoid commitment[37,38], was comparable among 3 groups. I*RF8* mRNA, a master regulator for monocytic and dendritic lineage differentiation[39,40], was higher in MPAL than AML-MP, consistent with the upregulated monocytic signatures (see Figure 5B). Notably, *CEBPA* mRNA, critical for myeloid differentiation[41], was higher in AML while both low in AML-MP and MPAL. In contrast, mRNA expression of *DNTT* and *LEF1*, both involved in lymphoid commitment[42,43], were significantly higher in MPAL than that in AML or AML-MP. In summary, AML-MP has higher levels of HSC transcription factors, while MPAL expresses higher levels of lymphoid transcription factors.

DISCUSSION

Our study for the first time provides evidence that most AML-MP clinically and biologically resembles its AML counterpart without MP but differs from MPAL, supporting the recommendation to exclude these patients from MPAL. This has important clinical implications as MPAL and AML-MP may be treated differently. Although there is no consensus on MPAL treatment, several retrospective studies have shown that induction therapy with ALL-type regimens is associated with superior outcomes particularly in pediatric patients with MPAL[6-10] while a recent study from our group demonstrated 94% (16/17) patients with MPAL achieved complete remission after receiving a hybrid myeloid and lymphoid induction regimen.[44] In contrast, the standard induction regimen for patients with AML-MRC/t-AML is liposomal formula of cytarabine and daunorubicin and more recently azacytidine and venetoclax.[11,45] Our data suggests that patients with AML-MP may be best managed as AML-MRC/t-AML rather than MPAL, although novel therapies are urgently needed to improve the outcomes of both entities.

Our study has demonstrated the importance of excluding other entities from the diagnosis of MPAL and has also better defined the boundary between AML-MP and MPAL. First, patients with *RUNX1* (with or without other MR) mutations but otherwise manifesting as MPAL, behave similarly to the remaining MPAL patients, indicating that the presence of *RUNX1* mutations, contradictory to the recommendation by ICC2022, may not justify these MPAL to be reclassified as AML-MP. More data are needed to elucidate the implications of other MR mutations in this regard.[46] Second, patients with driver fusions should be classified as such even if there is co-existing complex karyotype and/or *TP53* mutations. Our well annotated cohort study showed such adverse features (e.g. complex karyotype) typically seen in AML may not confer inferior outcome in *bona fide* MPAL, in contrast to a recent report.[47] Third, ICC2022 classification removed therapy-related AML as an entity, therefore, how to classify therapy-related AML with mixed phenotype warrants further scrutinizing. Such patients with TP53 mutations and monosomal/complex karyotype may be best classified as AML with TP53 mutations. This notion is supported by our data showing lack of TP53 mutations as driver in MPAL. Conversely, in patients considered as therapy-related AML based on treatment history but with neither TP53 mutations nor MDS related CG abnormalities, the classification of mixed phenotype requires comprehensive evaluation on a case-by-case basis. The data from our study indicate that the presence of nodal disease and/or mutations enriched for T-lymphoblastic lymphoma/leukemia (e.g. *NOTCH*, *JAK3*) may favor a diagnosis of MPAL in spite of prior cytotoxic therapy.

A unique finding of this study is the clusters identified by our novel unsupervised hierarchical clustering approach based on raw immunophenotypic files. Despite of the limited protein markers available (particularly no T-cell markers), this unbiased automated computational analysis accurately revealed immunophenotype, genotype and disease type correlation in certain clusters including cluster 5 as T/M phenotype, validating the utility of this approach. A recent study applied a similar approach to transcriptomes of a large cohort of so-called MPAL patients and identified 8 distinct clusters with immunophenotype and genotype correlation.[16] G1-G4 with T/M phenotype and G5-G8 with B/M phenotype. Interestingly, G2 and G3 were enriched for *NOTCH1* mutations but G2 had *DNMT3A* and G3 had *PHF6* mutations, two molecular subsets initially reported by our group.[14] G4 had FLT3 mutations and high expression level of *BCL11B*, consistent with a recently identified *BCL11B* rearranged T/M subset.[48,49] Intriguingly, G1 was exclusively *CEBPA* mutated with frequent *WT1* and *FLT3/RAS* mutations, likely representing bZIP *CEBPA* mutated AML, which often upregulates T-cell makers and can be misclassified as T/M MPAL.[50,51] G8 harbored *BCR::ABL1* fusions and high frequency of *RUNX1* co-mutations, a feature well described in CML BP, but rarely seen in MPAL.[52,53] As the inclusion criteria of our cohort are different with exclusion of CML BP (G8) and bZIP *CEBPA* mutations (G1) while including AML-MP and AML, a comparison between the two studies is nearly impossible. However, G2 likely corresponds to cluster 5 in our study as both are T/M enriched for *DNMT3A* mutations. Despite of these caveats, both studies demonstrate that unsupervised hierarchical clustering based on either transcriptome or surface protein expression is a powerful tool to study these diseases with a high degree immunophenotypic and genetic heterogeneity. Our data also show that although the majority of AML-MP is clustered differently from MPAL, there is an overlap between these two cohorts of patients, which may be due to limited protein markers in our flow panels and/or represent a real biological overlap. In future, an integrated approach combining FCS files, transcriptomes, chromatic accessibility, and genetics of a large cohort of AML-MP and MPAL may be required to further delineate these patients.

The observation that AML-MP has diminished lymphoid differentiation potential is intriguing. This implies that AML-MP and MPAL differ in biology despite share immunophenotypic heterogeneity. At mutational levels, MPAL lacks TP53 mutations and many (although not all) MR gene mutations. Our gene set pathway analysis showed upregulation of several HSC, leukemic stem cell and AML gene sets in AML-MP and AML without MP. The expression of genes that regulate HSC and leukemic stem cell biology such as *TAL1*, *GATA2*, *MEIS1*, *HOXB2*, and *HOXB3*.[33-36,54,55] was also upregulated in AML-MP

and AML without MP as compared to MPAL. Thus, primitive/HSC differentiation program is a shared feature between AML-MP and AML without MP, further supporting classifying AML-MP as AML rather than MPAL. In contrast, MPAL showed increased expression of transcription factors critical for lymphoid development. Consistent with our findings, previous studies using lineage deconvolution have shown that primitive/HSC signatures are enriched in *TP53* and *RUNX1* mutated AML and are associated with inferior outcomes.[56,57] In our small cohort of transcriptomes, a few patients with AML-MP grouped with MPAL, raising the possibility that the differential diagnosis between these two entities solely based on clinical history may not be perfect. Indeed, one of the AML-MP patients did not show HSC/MPP signatures or HSC gene set enrichment. Review of this patient's clinical and genetic data supported a diagnosis of MPAL rather than AML-MP, illustrating the additive value of transcriptome to the classification.

The genetic and epigenetic mechanisms for mixed phenotype in AML-MP remain unclear. *RUNX1* mutations were present in 40% of AML-MP, two times more common than AML without MP, implicating a role of *RUNX1* mutations in this process.[58] *RUNX1* has been shown to play an important role in lineage specification in hematopoietic and nonhematopoietic system.[59-65] *RUNX1* mutations lead to megakaryocytic differentiation block but increased plasmacytoid dendritic cell differentiation.[65,66] As *RUNX1* largely functions as a suppressor, loss-of-function mutations may result in imbalance of lineage specific (i.e. lymphoid) gene expression. The exact mechanism of how mutated *RUNX1* regulates lineage commitment awaits future studies. On the other hand, several studies have shown that immunophenotypically distinct blast compartments of MPAL harbor nearly identical genetic profile within a patient, and that cells from one lineage can reconstitute the alternate lineage in xenograft models,[13,14]suggesting that other factors beyond genetics may also contribute to phenotypic heterogeneity. Future studies combining cell barcoding and single cell multi-omic technology will provide better insights into this intriguing biological process.[67,68]

Acknowledgement:

This study was funded in part through the NIH/NCI Cancer Center Support Grant P30 CA008748. P.G. and A.C. are supported by grants from Department of Pathology and Laboratory Medicine at MSKCC. R.L.L. is supported by a Cycle for Survival Innovation Grant and National Cancer Institute R35 CA197594. J.L.G. is supported by a National Cancer Institute grant (NCI K08CA230172) and Equinox Cycle for Survival. WX is supported by Alex's Lemonade Stand Foundation and the Runx1 Research Program, a Cycle for Survival's Equinox Innovation Award in Rare Cancers, MSK Leukemia SPORE (Career Enhancement Program, NIH/NCI P50 CA254838) and a National Cancer Institute grant (K08CA267058).

Authorship contributions:

P.G., A.C., M.R. and W.X. identified patients and reviewed pathology. D.D. and J.G. performed automated flow cytometric analysis, analyzed RNA-seq data, and plotted figures. Y.Z. reviewed cytogenetic data. A.DerKach. performed statistical analysis. S.P., T.M. and Q.G. helped sorting. Y.L. and M.A. helped mutational analysis. A.Dogan. and R.L.L. supervised the project. W.X. initiated, designed, and supervised the study. P.G. and W.X. wrote and all authors approved the manuscript.

Conflict of Interest:

M.A served as consultant for Janssen Global Services, Bristol-Myers Squibb, AstraZeneca, and Roche; and has received honoraria from Biocartis, Invivoscribe, physician educational resources (PER), Peerview Institute for medical education, clinical care options, RMEI medical education. RLL is on the supervisory board of Qiagen and is a scientific advisor to Imago, Mission Bio, Syndax. Zentalis, Ajax, Bakx, Auron, Prelude, C4 Therapeutics and Isoplexis for which he receives equity support. RLL receives research support from Ajax and Abbvie and has consulted for Incyte, Janssen, Morphosys and Novartis. He has received honoraria from Astra Zeneca and Kura for invited lectures and from Gilead for grant reviews. M.R. is on the scientific advisory board in Auron Pharmaceutical for which he received equity support. He receives research funding from Celularity, Roche-Genentech, Beat AML and NGM and travel fund from BD Biosciences. J.L.G. received consulting fees from GLG.W.X. has received research support from Stemline Therapeutics. P.G. has received research support from Paige.AI. M.B.G. has received research support from Sanofi, Amgen, and Actinium Pharmaceuticals, Inc., and has consulted for Novartis and Sanofi.

References:

1. Jaffe E, Swerdlow SHCE, Campo E, et al. WHO Classification of Tumours of the Haematopoietic and Lymphoid Tissues. Vol. 2; 2008.
2. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues.; 2017.
3. Kajal B, Chang H. Acute myeloid leukemia with myelodysplasia-related changes demonstrating mixed-lineage phenotype. *Blood*. 2016;128(12):1663-1663.
4. Klairmont MM, Cheng J, Gradowski JF. AML with MDS-related changes and blasts of mixed lineage: time for a new provisional entity? *Leuk Lymphoma*. 2018;59(11):2752-2754.
5. Matutes E, Pickl WF, Van't Veer M, et al. Mixed-phenotype acute leukemia: clinical and laboratory features and outcome in 100 patients defined according to the WHO 2008 classification. *Blood*. 2011;117(11):3163-3171.
6. Hrusak O, de Haas V, Stancikova J, et al. International cooperative study identifies treatment strategy in childhood ambiguous lineage leukemia. *Blood*. 2018;132(3):264-276.
7. Duong VH, Begna KH, Kashanian S, et al. Favorable outcomes of acute leukemias of ambiguous lineage treated with hyperCVAD: a multi-center retrospective study. *Ann Hematol*. 2020;99(9):2119-2124.
8. Orgel E, Alexander TB, Wood BL, et al. Mixed-phenotype acute leukemia: A cohort and consensus research strategy from the Children's Oncology Group Acute Leukemia of Ambiguous Lineage Task Force. *Cancer*. 2020;126(3):593-601.
9. Rasekh EO, Osman R, Ibraheem D, et al. Acute lymphoblastic leukemia-like treatment regimen provides better response in mixed phenotype acute leukemia: a comparative study between adults and pediatric MPAL patients. *Ann Hematol*. 2021;100(3):699-707.
10. Lazzarotto D, Tanasi I, Vitale A, et al. Multicenter retrospective analysis of clinical outcome of adult patients with mixed-phenotype acute leukemia treated with acute myeloid leukemia-like or acute lymphoblastic leukemia-like chemotherapy and impact of allogeneic stem cell transplantation: a Campus ALL study. *Ann Hematol*. 2023;102(5):1099-1109.
11. Lancet JE, Cortes JE, Hogge DE, et al. Phase 2 trial of CPX-351, a fixed 5:1 molar ratio of cytarabine/daunorubicin, vs cytarabine/daunorubicin in older adults with untreated AML. *Blood*. 2014;123(21):3239-3246.
12. Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. *Leukemia*. 2022;36(7):1703-1719.
13. Alexander TB, Gu Z, Iacobucci I, et al. The genetic basis and cell of origin of mixed phenotype acute leukaemia. *Nature*. 2018;562(7727):373-379.
14. Xiao W, Bharadwaj M, Levine M, et al. PHF6 and DNMT3A mutations are enriched in distinct subgroups of mixed phenotype acute leukemia with T-lineage differentiation. *Blood Adv*. 2018;2(23):3526-3539.
15. Takahashi K, Wang F, Morita K, et al. Integrative genomic analysis of adult mixed phenotype acute leukemia delineates lineage associated molecular subtypes. *Nat Commun*. 2018;9(1):2670.
16. Wang Q, Cai WZ, Wang QR, et al. Integrative genomic and transcriptomic profiling reveals distinct molecular subsets in adult mixed phenotype acute leukemia. *Am J Hematol*. 2023;98(1):66-78.
17. Peretz CAC, Kennedy VE, Walia A, et al. Multiomic Single Cell Sequencing Identifies Stemlike Nature of Mixed Phenotype Acute Leukemia and Provides Novel Risk Stratification. *bioRxiv*. 2023:2023.2005.2015.540305.
18. Lindsley RC, Mar BG, Mazzola E, et al. Acute myeloid leukemia ontogeny is defined by distinct somatic mutations. *Blood*. 2015;125(9):1367-1376.
19. McCarter JGW, Nemirovsky D, Famulare CA, et al. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. *Blood Adv*. 2023;7(17):5000-5013.

20. Boddu P, Kantarjian HM, Garcia-Manero G, et al. Treated secondary acute myeloid leukemia: a distinct high-risk subset of AML with adverse prognosis. *Blood Adv*. 2017;1(17):1312-1323.
21. Arber DA, Orazi A, Hasserjian RP, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. *Blood*. 2022;140(11):1200-1228.
22. Weinberg OK, Arber DA, Döhner H, et al. The International Consensus Classification of acute leukemias of ambiguous lineage. *Blood*. 2023;141(18):2275-2277.
23. Zeijlemaker W, Grob T, Meijer R, et al. CD34(+)CD38(-) leukemic stem cell frequency to predict outcome in acute myeloid leukemia. *Leukemia*. 2019;33(5):1102-1112.
24. Goardon N, Marchi E, Atzberger A, et al. Coexistence of LMPP-like and GMP-like leukemia stem cells in acute myeloid leukemia. *Cancer Cell*. 2011;19(1):138-152.
25. Dohner H, Estey E, Grimwade D, et al. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. *Blood*. 2017;129(4):424-447.
26. Corces MR, Buenrostro JD, Wu B, et al. Lineage-specific and single-cell chromatin accessibility charts human hematopoiesis and leukemia evolution. *Nat Genet*. 2016;48(10):1193-1203.
27. Subramanian A, Tamayo P, Mootha VK, et al. Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. *Proc Natl Acad Sci U S A*. 2005;102(43):15545-15550.
28. Liberzon A, Subramanian A, Pinchback R, Thorvaldsdóttir H, Tamayo P, Mesirov JP. Molecular signatures database (MSigDB) 3.0. *Bioinformatics*. 2011;27(12):1739-1740.
29. Jaatinen T, Hemmoranta H, Hautaniemi S, et al. Global gene expression profile of human cord blood-derived CD133+ cells. *Stem Cells*. 2006;24(3):631-641.
30. Valk PJ, Verhaak RG, Beijen MA, et al. Prognostically useful gene-expression profiles in acute myeloid leukemia. *N Engl J Med*. 2004;350(16):1617-1628.
31. Takeda A, Goolsby C, Yaseen NR. NUP98-HOXA9 induces long-term proliferation and blocks differentiation of primary human CD34+ hematopoietic cells. *Cancer Res*. 2006;66(13):6628-6637.
32. Gentles AJ, Plevritis SK, Majeti R, Alizadeh AA. Association of a leukemic stem cell gene expression signature with clinical outcomes in acute myeloid leukemia. *Jama*. 2010;304(24):2706-2715.
33. Shivdasani RA, Mayer EL, Orkin SH. Absence of blood formation in mice lacking the T-cell leukaemia oncoprotein tal-1/SCL. *Nature*. 1995;373(6513):432-434.
34. Robb L, Lyons I, Li R, et al. Absence of yolk sac hematopoiesis from mice with a targeted disruption of the scl gene. *Proc Natl Acad Sci U S A*. 1995;92(15):7075-7079.
35. Ling KW, Ottersbach K, van Hamburg JP, et al. GATA-2 plays two functionally distinct roles during the ontogeny of hematopoietic stem cells. *J Exp Med*. 2004;200(7):871-882.
36. Suzuki N, Ohneda O, Minegishi N, et al. Combinatorial Gata2 and Sca1 expression defines hematopoietic stem cells in the bone marrow niche. *Proc Natl Acad Sci U S A*. 2006;103(7):2202-2207.
37. Rosenbauer F, Owens BM, Yu L, et al. Lymphoid cell growth and transformation are suppressed by a key regulatory element of the gene encoding PU.1. *Nat Genet*. 2006;38(1):27-37.
38. Nerlov C, Graf T. PU.1 induces myeloid lineage commitment in multipotent hematopoietic progenitors. *Genes Dev*. 1998;12(15):2403-2412.
39. Kurotaki D, Yamamoto M, Nishiyama A, et al. IRF8 inhibits C/EBPα activity to restrain mononuclear phagocyte progenitors from differentiating into neutrophils. *Nat Commun*. 2014;5:4978.
40. Sichien D, Scott CL, Martens L, et al. IRF8 Transcription Factor Controls Survival and Function of Terminally Differentiated Conventional and Plasmacytoid Dendritic Cells, Respectively. *Immunity*. 2016;45(3):626-640.
41. Avellino R, Delwel R. Expression and regulation of C/EBPα in normal myelopoiesis and in malignant transformation. *Blood*. 2017;129(15):2083-2091.
42. Klein F, Roux J, Cvijetic G, et al. Dntt expression reveals developmental hierarchy and lineage specification of hematopoietic progenitors. *Nat Immunol*. 2022;23(4):505-517.

43. Travis A, Amsterdam A, Belanger C, Grosschedl R. LEF-1, a gene encoding a lymphoid-specific protein with an HMG domain, regulates T-cell receptor alpha enhancer function [corrected]. *Genes Dev*. 1991;5(5):880-894.
44. Atchley E, Weis TM, Derkach A, et al. Outcomes with high dose cytarabine and mitoxantrone induction for adults with mixed phenotype acute leukemia. *Leuk Res*. 2023;130:107311.
45. DiNardo CD, Pratz K, Pullarkat V, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. *Blood*. 2019;133(1):7-17.
46. McCarter JGW, Nemirovsky D, Famulare CA, et al. Interaction between myelodysplasia-related gene mutations and ontogeny in acute myeloid leukemia. *Blood Adv*. 2023.
47. Kirtek T, Chen W, Laczko D, et al. Acute leukemias with complex karyotype show a similarly poor outcome independent of mixed, myeloid or lymphoblastic immunophenotype: A study from the Bone Marrow Pathology Group. *Leukemia Research*. 2023;130:107309.
48. Di Giacomo D, La Starza R, Gorello P, et al. 14q32 rearrangements deregulating BCL11B mark a distinct subgroup of T-lymphoid and myeloid immature acute leukemia. *Blood*. 2021;138(9):773-784.
49. Montefiori LE, Bendig S, Gu Z, et al. Enhancer Hijacking Drives Oncogenic BCL11B Expression in Lineage-Ambiguous Stem Cell Leukemia. *Cancer Discov*. 2021;11(11):2846-2867.
50. Lin LI, Chen CY, Lin DT, et al. Characterization of CEBPA mutations in acute myeloid leukemia: most patients with CEBPA mutations have biallelic mutations and show a distinct immunophenotype of the leukemic cells. *Clin Cancer Res*. 2005;11(4):1372-1379.
51. Mannelli F, Ponziani V, Bencini S, et al. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. *Haematologica*. 2017;102(3):529-540.
52. Zhao LJ, Wang YY, Li G, et al. Functional features of RUNX1 mutants in acute transformation of chronic myeloid leukemia and their contribution to inducing murine full-blown leukemia. *Blood*. 2012;119(12):2873-2882.
53. Branford S, Kim DDH, Apperley JF, et al. Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia. *Leukemia*. 2019;33(8):1835-1850.
54. Rozovskaia T, Feinstein E, Mor O, et al. Upregulation of Meis1 and HoxA9 in acute lymphocytic leukemias with the t(4 : 11) abnormality. *Oncogene*. 2001;20(7):874-878.
55. Armstrong SA, Staunton JE, Silverman LB, et al. MLL translocations specify a distinct gene expression profile that distinguishes a unique leukemia. *Nat Genet*. 2002;30(1):41-47.
56. van Galen P, Hovestadt V, Wadsworth II MH, et al. Single-Cell RNA-Seq Reveals AML Hierarchies Relevant to Disease Progression and Immunity. *Cell*. 2019;176(6):1265-1281.e1224.
57. Zeng AGX, Bansal S, Jin L, et al. A cellular hierarchy framework for understanding heterogeneity and predicting drug response in acute myeloid leukemia. *Nat Med*. 2022;28(6):1212-1223.
58. Granja JM, Klemm S, McGinnis LM, et al. Single-cell multiomic analysis identifies regulatory programs in mixed-phenotype acute leukemia. *Nature Biotechnology*. 2019;37(12):1458-1465.
59. North TE, de Bruijn MF, Stacy T, et al. Runx1 expression marks long-term repopulating hematopoietic stem cells in the midgestation mouse embryo. *Immunity*. 2002;16(5):661-672.
60. Mevel R, Steiner I, Mason S, et al. RUNX1 marks a luminal castration-resistant lineage established at the onset of prostate development. *Elife*. 2020;9.
61. Kellaway SG, Keane P, Kennett E, Bonifer C. RUNX1-EVI1 disrupts lineage determination and the cell cycle by interfering with RUNX1 and EVI1 driven gene regulatory networks. *Haematologica*. 2021;106(6):1569-1580.
62. Hu Z, Gu X, Baraoidan K, et al. RUNX1 regulates corepressor interactions of PU.1. *Blood*. 2011;117(24):6498-6508.
63. Kuvardina ON, Herglotz J, Kolodziej S, et al. RUNX1 represses the erythroid gene expression program during megakaryocytic differentiation. *Blood*. 2015;125(23):3570-3579.
64. Draper JE, Sroczynska P, Leong HS, et al. Mouse RUNX1C regulates premegakaryocytic/erythroid output and maintains survival of megakaryocyte progenitors. *Blood*. 2017;130(3):271-284.

65. Wang C, Tu Z, Cai X, et al. A Critical Role of RUNX1 in Governing Megakaryocyte-Primed Hematopoietic Stem Cell Differentiation. *Blood Adv*. 2023.
66. Xiao W, Chan A, Waarts MR, et al. Plasmacytoid dendritic cell expansion defines a distinct subset of RUNX1-mutated acute myeloid leukemia. *Blood*. 2021;137(10):1377-1391.
67. Goyal Y, Busch GT, Pillai M, et al. Diverse clonal fates emerge upon drug treatment of homogeneous cancer cells. *Nature*. 2023.
68. Zeller C, Richter D, Jurinovic V, et al. Adverse stem cell clones within a single patient's tumor predict clinical outcome in AML patients. *J Hematol Oncol*. 2022;15(1):25.

Table 1. Clinicopathological Characteristics of patients with AML-MP and MPAL

	MPAL	AML	AML-MP			
			Total	B/Myeloid	T/Myeloid	B/T/Myeloid
Age, median years (Range)	42 (0-85.5)	70 (14-87)	66.5 (8.5-85)	68 (34-81)	71 (8.5-85)	51 (37-68)
Gender (M/F)	27/18	65/35	33/22	15/15	15/5	3/2
CBC prior to induction						
WBC, median X 10*9/L (Range)	12.9 (0.7-323)	2.4 (0.1-89)	2.9 (0.4-75.8)	2.7 (0.6-75.8)	6.6 (0.4-52.2)	2.15 (1.4-14.6)
Hb, median g/dL (Range)	9.1 (6-15.1)	8.7 (5.8-15.7)	8.5 (6.3-12.8)	8.45 (6.5-10.8)	8.6 (6.3-12.8)	8.5 (6.7-10.9)
PLT, median X 10*9/L (Range)	93 (13-403)	46.5 (7-893)	51 (2-350)	57 (14-350)	40 (2-333)	84.5 (27-195)
Blasts, median % (Range)	27 (0-94)	7 (0-88.3)	11.5 (0-87)	14.5 (0-75)	12 (0-87)	0 (0-20)
Bone Marrow findings						
Blasts, median % (Range)	75 (1-100)	30 (7-92)	48 (8-88)	50 (8-88)	56 (8-90)	44 (14-58)
Extramedullary involvement						
Lymph node	11	3	7	0	6	1
Skin	1	5	7	7	0	0
WHO classification						
MPAL with t(v;11q23.3)	5	0	0	0	0	0
MPAL with t(9;22)	6	0	0	0	0	0
MPAL, B/myeloid, NOS	15	0	0	0	0	0
MPAL, T/myeloid, NOS	16	0	0	0	0	0
MPAL, NOS*	3	0	0	0	0	0

t-AML	0	37	15	10	3	2
AML-MRC	0	63	40	20	17	3
Blast population						
Orthogonal bilineal blasts	35	NA	47	26	16	5
Biphenotypic blasts	3	NA	6	4	4	0
Unknown	7		2			
History of prior myeloid neoplasm	0	67	21	12	7	2
History of Chemotherapy	0	37	15	10	3	2
Cytogenetics						
CK with chr 5, 7, 17 abnorm.	2	38	21	9	10	2
CK w/o chr 5, 7, 17 abnorm.	7	8	4	2	1	1
Chr 5, 7, 17 abnorm. w/o CK	0	18	17	11	5	1
Other MDS-CG	0	2	2	1	1	0
Induction with intension to cure	43/44	52/92	42/51	24/28	14/18	4/5
Myeloid regimen	15	52	36	24	11	1
Lymphoid regimen	19	NA	2	0	2	0
Hybrid regimen	9	NA	4	0	1	3
Complete remission	38/42	30/92	18/48	12/47	5/47	2/47
Persistent Disease	4/42	62/92	29/48	16/47	11/47	1/47
Hematopoietic Stem Cell Transplant	28	33	18	10	6	2

Note: w/o, without. MDS-CG, MDS defining cytogenetic abnormalities. CK, complex karyotypes; abnorm, abnormalities. WBC, white blood cells; Hb, hemoglobin; PLT, platelets.

Figure legend

FIGURE 1: Diagnostic algorithm for AML-MP and MPAL. A. Inclusion and exclusion criteria of AML-MP and MPAL cohorts. Only 1/3 of these patients had bona fide MPAL. Abbreviations: CML BP, chronic myeloid leukemia with blast phase; MPN BP, myeloproliferative neoplasm with blast phase; B-ALL with iso MPO, B-acute lymphoblastic leukemia with isolated myeloperoxidase expression; AML with RCA, acute myeloid leukemia with recurrent cytogenetic abnormalities; M/L, myeloid and lymphoid; AML-MRC, acute myeloid leukemia with myelodysplasia-related changes; t-AML, therapy-related AML; MPAL, mixed phenotype acute leukemia. **B.** Pie chart of the AML-MP cohort detailing the inclusion criteria namely prior history of cytotoxic chemotherapy and/or radiotherapy administered for a non-myeloid neoplastic or non-neoplastic disorder for t-AML (15 cases) and prior history of MDS and/or MDS/MPN and/or the presence of MDS defining cytogenetic abnormalities for AML-MRC (39 cases; 6 cases with prior history of MDS and/or MDS/MPN only, 26 cases with MDS defining cytogenetic abnormalities only, and 7 cases with both). 1 case lacking both history of MDS and/or MDS/MPN and MDS defining cytogenetic abnormalities had mutational profile typical for AML and was classified as AML-MRC. MR.RUNX1 represents patients with *MR* and *RUNX1* comutations. MR represents patients with *MR* mutations (not including *RUNX1*). RUNX1 represents patients with *RUNX1* mutations while no other *MR* mutations. MR mutations include mutations in any of these genes: *ASXL1, BCOR, EZH2, STAG2, SF3B1, SRSF2, U2AF1,* and *ZRSR2*. MDS-CG, MDS related cytogenetic abnormalities which included complex karyotype (≥ 3 abnormalities), 5q deletion or loss of 5q due to unbalanced translocation, monosomy 7, 7q deletion, or loss of 7q due to unbalanced translocation, 11q deletion, 12p deletion or loss of 12p due to unbalanced translocation, monosomy 13 or 13q deletion, 17p deletion or loss of 17p due to unbalanced translocation, isochromosome 17q and idic(X)(q13)[12]. Abbreviations: MDS, myelodysplastic syndrome/neoplasm; MDS/MPN, myelodysplastic and myeloproliferative overlap syndrome.

FIGURE 2: Landscape of gene mutations and cytogenetic abnormalities in AML-MP and MPAL. A. The oncoplot tabulates mutations, fusions, cytogenetics, prior history of cytotoxic chemotherapy and/or radiotherapy, prior history of MDS and/or MDS/MPN for all the 3 cohorts (AML-MP, MPAL and AML without MP) along with the blast lineage and CD38 expression intensity annotated on the bottom bar. B blasts, B-lineage blasts; M blasts, myeloid lineage blasts; T-blasts, T-lineage blasts. SNV, single nucleotide variant. Chr5/7/17, MDS-cytogenetic abnormalities involving chromosomes 5, 7 or 17 but not qualifying for complex karyotype; CK w/ Chr5/7/17, complex karyotype with MDS defining cytogenetic abnormalities involving chromosomes 5, 7 or 17; CK w/o Chr5/7/17, complex karyotype but not involving chromosomes 5, 7 or 17. B. Bar graphs showing pairwise comparisons of mutation and fusion frequencies within the 3 cohorts, containing statistical significance bars ($p = < 0.05$) in black and trend towards significance in blue.

FIGURE 3: Unsupervised hierarchal clustering based on automated immunophenotypic data of AML-MP and MPAL. Hierarchical clustering (Euclidean distance, Ward's method) was used to create eight distinct groups of patients based on automated analysis on raw clinical flow cytometry data in the form of FCS files of M1 and M2 tubes from the 3 cohorts (see Supplemental Table S1). The automated analysis was contrast with manually annotated immunophenotype as indicated by CD markers. Additionally, disease type, blast lineage, cytogenetics, prior history, mutations, and fusions were also listed.

FIGURE 4: Outcome of AML-MP and MPAL. A. Kaplan-Meier survival curves stratified by disease type.Red line, MPAL; green line, AML without mixed phenotype; blue line, AML with mixed phenotype (AML-MP). **B**. A forest plot indicating hazards ratios per clinical predictors including age, treatment with intension to cure (TreatmentToCures), cytogenetic risk stratification category and allotransplant (INTOallo received). **C.** Kaplan-Meier survival curves stratified by immunophenotypic clusters generated unsupervised hierarchal clustering (Figure 3). **D.** Kaplan-Meier survival curves after re-classifying MPAL cases according to the presence of *MR/RUNX1* gene mutations. Black line, MPAL patients harboring *RUNX1* (with or without *MR*) mutations; red line, MPAL patients with no *MR/RUNX1* mutations. **E.** Kaplan-Meier survival curves after stratifying MPAL cases according to the presence or absence of complex karyotype within the MPAL cohort. Yellow line, MPAL patients with complex karyotypes; red line, MPAL patients without complex karyotypes.

FIGURE 5: Enriched stemness transcriptomic signatures in AML-MP. A. Principal components analysis (PCA) conducted on RNA-seq, colored by disease type. **B.** Gene set enrichment tests comparing AML-MP and MPAL cases. The mean statistic for gene contrasts (in both positive and negative directions) is displayed per stage, with statistical significance ($p = < 0.05$) of the enrichment test indicated. Enrichment was conducted using contrived gene sets per hematopoietic lineage stage, indicating high HSC enrichment in AML-MP samples and high monocytic and CD4 positive T-cell lineage enrichment in myeloid and T- blasts in MPAL samples. HSC, hematopoietic stem cells; MPP, multipotent progenitors; LMPP, lymphoid myeloid potent progenitors; CMP, common myeloid progenitors; GMP, granulocytic and monocytic progenitors; MEP, megakaryocytic and erythroid progenitors; CLP, common lymphoid progenitors; Ery, erythroid; NK, nature killer cells. **C.** Gene set enrichment analysis (GSEA) comparing AML-MP and MPAL cases, indicating stem cell enrichment in AML-MP. **D.** Gene set variation analysis (GSVA) clustered using hierarchical analysis (Euclidean distance, Ward's method). AML-MP2 (a ~75-79-year-old female), clustering with MPAL, had therapy related history for breast cancer but presented with lymphadenopathy showing T-ALL and blasts in the marrow revealed T/M phenotype. Genetics showed normal karyotype and *JAK3/NRAS* mutations, and therefore would be best classified as MPAL rather than t-AML. **E.** Select RNA-seq gene expression stratified by disease type. Among the genes upregulated in AML-MP and AML without MP samples were several master regulators of hematopoiesis such as MEIS1, HOXB2, and HOXB3.

Figure 6: Limited lymphoid potential of AML-MP but not MPAL. A. Heatmap split by disease type, depicting blast percentages alongside blast immunophenotype per time point, treatment types and responses. Dx, diagnosis; CR MRD, complete remission, measurable residual disease; neg, negative; pos, positive; MLFS, morphologic leukemia free state; PPRS, partial, persistent, or refractory response. **B and C.** Alluvial plots per disease type exhibiting shifts in lineage between diagnosis, treatment, and relapse time points. **D.** Bar graphs comparing lineage shift post treatment, either post induction or relapse. M, myeloid blasts; L, lymphoid blasts. **E.** Floating bar charts depicting mRNA expression levels of select transcription factors critical for myeloid versus lymphoid lineage commitment.


A
Acute leukemia with mixed phenotype by WHO 2017 definition (n=137)
CML BP (n=18)
MPN BP (n=3)
B-ALL with iso MPO (n=7)
AML with RCA (n=7)
M/L neoplasm with rearrangements and hypereosinophilia (n=2)
AML-MRC and tAML (AML-MP) (n=55)
de novo MPAL (n=45)


B
Mutations
TP53
MR.RUNX1
RUNX1
MR
Other
Unknown
MDS–CG
MDS_CG
No_MDS_CG
Unknown
Prior History
Radiation/Chemotherapy
MDS or MDS/MPN
None


A
RUNX1
TP53
DNMT3A
TET2
ASXL1
FLT3
IDH2
SF3B1
NRAS
KRAS
IDH1
SRSF2
CEBPA
PHF6
PTPN11
WT1
U2AF1
JAK1
ETV6
BCOR
STAG2
EZH2
SUZ12
SETBP1
MPL
JAK3
ZRSR2
KMT2A
BCR-ABL1
PICALM-MLLT10
EVI1
SET-NUP214
ETV6
ETV6-NTRK3
ETV6-RUNX1
MEF2C-CD109
MYST3-CREBBP
NUP98-NSD1
SSBP2-JAK2
I(1;3)
I(2;11)
Type
Cytogenetics
Prior.History
CD38
Single.Blast
B.Blast
M.Blast
T.Blast
Alterations
deletion
frameshift
splicing
SNV
insertion
not present
unknown
Alterations
fusion
not present
unknown
Type
MPAL
AML-MP
AML
Cytogenetics
Chr 5/7/17
CK w/Chr 5/7/17
CK w/o Chr 5/7/17
Other
Other MDS CG
Prior.History
MDS or MDS/MPN
Radiation/Chemotherapy
None
CD38
0
1
2
3
unknown
B
%
RUNX1
TP53
SRSF2
U2AF1
DNMT3A
BCOR
ASXL1
TET2
STAG2
SETBP1
NRAS
PTPN11
FLT3
KRAS
PHF6
IDH2
CEBPA
SF3B1
IDH1
EZH2
BCR-ABL1 fusion
KMT2A fusion
PICALM-MLLT10 fusion
type
MPAL
AML-MP
AML


Type
Lineage
Cytogenetics
Prior.History
Cluster.No
5
7
3
8
1
6
4
2
CD34
HLADR
CD13
CD117
CD33
CD38
MPO
CD7
CD56
CD11b
CD64
cCD3
CD5
CD22
CD16
CD19
cyCD79a
CD10
RUNX1
TP53
TET2
DNMT3A
ASXL1
NRAS
FLT3
IDH1
SRSF2
KRAS
IDH2
SF3B1
U2AF1
CEBPA
BCOR
STAG2
ETV6
PTPN11
PHF6
WT1
EZH2
0 10 20 30
BCR–ABL1
KMT2A
PICALM–MLLT10
ETV6
ETV6–NTRK3
ETV6–RUNX1
EVI1
SSBP2–JAK2
0 2 4
Single.Blast
B.Blast
M.Blast
T.Blast
Type
MPAL
AML–MP
AML
Lineage
B/M
M
T/B/M
T/M
Cytogenetics
Chr 5/7/17
CK w/Chr 5/7/17
CK w/o Chr 5/7/17
Other
Other MDS CG
Prior.History
None
MDS or MDS/MPN
Radiation/Chemotherapy
Cluster.No
1
2
3
4
5
6
7
8
Automated
15
10
5
0
−5
Manual
3
2
1
0
Alterations
deletion
splicing
SNV
insertion
not present
unknown
Alterations
fusion
not present
unknown
Blast %
100
50
0


A
Overall Survival
1.00
0.75
0.50
0.25
0.00
0
25
50
75
100
125
Time in Month from C1D1
Number at risk
Type:
AML−MP 32 8 5 2 1 1
de novo MPAL 20 27 17 10 2 0
AML 49 13 5 0 0 0
Time in Month from C1D1
B
Variable
Age (>65 vs <65)
p = 0.031
Cohort (AML vs AML−MP)
p = 0.387
Gender (Male vs Female)
p = 0.868
Allo Transplant (Received vs Not Received)
p = 0.065
Treatment To Cure (Received vs Not Received)
p = 0.021
Cohort (De Novo vs AML−MP)
p = 0.001
0
1
2
3
4
Hazard Ratio
C
Overall Survival
Time in Month from C1D1
Number at risk
Cohort:
1 5 8 4 2 0
2 15 5 1 1 0
3 15 3 2 0 0
4 13 6 5 0 0
5 4 0 0 0 0
6 10 2 0 0 0
7 11 3 3 1 0
8 8 5 3 2 0
Time in Month from C1D1
D
Overall Survival
Time in Month from C1D1
Number at risk
Type:
AML−MP 32 8 5 2 1 1
De Novo MPAL 16 21 14 9 2 0
ICC re−classified 8 6 3 1 0 0
AML 49 13 5 0 0 0
Time in Month from C1D1
E
Overall Survival
Time in Month from C1D1
Number at risk
Type:
AML−MP 32 8 5 2 1 1
de novo MPAL with CK 7 4 3 2 0 0
de novo MPAL without CK 16 23 14 8 2 0
AML 49 13 5 0 0 0
Time in Month from C1D1


A
PCA: RNA-seq
PC2: 14% variance
PC1: 20% variance
Group
MPAL
AML−MP
AML
B
Gene Contrast per Lineage Stage
MPAL vs. AML-MP
Myeloid subset
T subset
HSC
MPP
LMPP
CMP
GMP
MEP
Mono
Ery
CLP
CD4
CD8
B
NK
Stat (Mean)
Stage
C
GSEA
AML MP vs MPAL, T tube
Jaatinen
Hematopoetic Stem Cell
Takeda Targets
NUP98 HOX89 Fusion 10D
AML MP vs MPAL, M tube
Valk
AML Cluster 15
Booquest
Stem Cell Up
D
Gene Set Variation Analysis
JAATINEN
HEMATOPOIETIC_STEM_CELL
VALK
AML_CLUSTER_15
TAKEDA_TARGETS
NUP98_HOXA9_FUSION_10D
BOQUEST
STEM_CELL
GENTLES
LEUKEMIC_STEM_CELL
GSVA
Disease.Type
AML
AML−MP
MPAL
CD38
1
2
Disease.Type
CD38
E
RNA-Seq: Valk and LSC Genes
LAPTM4B
SEL1L3
GRAMD1B
KLF9
HTR1F
MEIS1
RBPMS
SUCLG2
BASP1
ARHGAP22
HOXA5
ABCB4
CEACAM8
CFHR1
HOXB5
DPYSL3
PLSCR4
HOXB2
HOXB3
HLF
MECOM
CACNB2
ZNF165
SMARCA1
Disease


A
AML-MP
MPAL
100
50
0
Blasts
Treatment
Response
Death
Dx
Post.Induction
Relapse 1
Relapse 2
Response
CR MRD neg
CR MRD pos
MLFS
PPRS
Unknown
Treatment
Both
L
M
Unknown
Death
Lineage at Diagnosis, Post-Induction, & Relapse
B
B/M
B/T
M
T
T/B/M
T/M
Single.Blast
NEG
Unknown
B
AML−MP: Lineage Dynamics
Patients (N)
40
20
0
Dx
Post.Induction
Relapse 1
Relapse 2
Time Point
C
MPAL: Lineage Dynamics
B/M
T/M
T/B/M
B/T
T
B
M
Single.Blast
NEG
Unknown
D
M vs L Immunophenotype
***
30%
20%
10%
0%
Percent
M
L
AML−MP
MPAL
Disease
E
RNA
15
10
5
0
0.008**
0.008**
0.036*
0.012*
0.006**
0.043*
0.006**
0.012*
0.006**
0.006**
TAL1
GATA2
CEBPA
DNTT
LEF1
IRF8
SPI1
Disease Type
AML
AML−MP
MPAL